BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33641031)

  • 1. The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors.
    Timmins HC; Li T; Goldstein D; Trinh T; Mizrahi D; Harrison M; Horvath LG; Friedlander M; Kiernan MC; Park SB
    J Cancer Surviv; 2022 Apr; 16(2):223-232. PubMed ID: 33641031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review.
    Timmins HC; Mizrahi D; Li T; Kiernan MC; Goldstein D; Park SB
    J Cancer Surviv; 2023 Feb; 17(1):222-236. PubMed ID: 33438175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
    Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
    Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes.
    Battaglini E; Goldstein D; Grimison P; McCullough S; Mendoza-Jones P; Park SB
    J Natl Compr Canc Netw; 2021 Jul; 19(7):821-828. PubMed ID: 34340206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
    Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
    Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upper-limb dysfunction in cancer survivors with chemotherapy-induced peripheral neurotoxicity.
    Mahfouz FM; Li T; Joda M; Harrison M; Kumar S; Horvath LG; Grimison P; King T; Goldstein D; Park SB
    J Neurol Sci; 2024 Feb; 457():122862. PubMed ID: 38185015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy.
    McCrary JM; Goldstein D; Sandler CX; Barry BK; Marthick M; Timmins HC; Li T; Horvath L; Grimison P; Park SB
    Support Care Cancer; 2019 Oct; 27(10):3849-3857. PubMed ID: 30756229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test.
    McCrary JM; Goldstein D; Wyld D; Henderson R; Lewis CR; Park SB
    J Cancer Surviv; 2019 Aug; 13(4):495-502. PubMed ID: 31172429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors.
    Teng C; ; Blinman PL; Vardy JL
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1308-1315. PubMed ID: 36509075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial.
    Lemanska A; Harkin A; Iveson T; Kelly C; Saunders M; Faithfull S
    ESMO Open; 2023 Dec; 8(6):102063. PubMed ID: 37988949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments.
    McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Menant J; Friedlander M; Lewis CR; Hertzberg M; O'Neill S; King T; Bosco A; Harrison M; Park SB
    J Natl Compr Canc Netw; 2019 Aug; 17(8):949-955. PubMed ID: 31390588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine Stress Axis-Dependence of Duloxetine Analgesia (Anti-Hyperalgesia) in Chemotherapy-Induced Peripheral Neuropathy.
    Staurengo-Ferrari L; Bonet IJM; Araldi D; Green PG; Levine JD
    J Neurosci; 2022 Jan; 42(3):405-415. PubMed ID: 34880120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
    Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort.
    Sreeram K; Seaton R; Greenwald MK; Kamgar M; Assad H; Baird T; Schwartz AG; Ruterbusch J; Simon MS
    Cancer Causes Control; 2023 May; 34(5):459-468. PubMed ID: 36934365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.
    Balayssac D; Kerckhove N; Selvy M; Pereira B; Gonneau C; Pétorin C; Vimal-Baguet A; Melnikov S; Kullab S; Hebbar M; Bouché O; Slimano F; Bourgeois V; Lebrun-Ly V; Thuillier F; Mazard T; Tavan D; Benmammar KE; Monange B; Ramdani M; Péré-Vergé D; Huet-Penz F; Bedjaoui A; Genty F; Leyronnas C; Pezet D; Martin V
    Support Care Cancer; 2024 Jun; 32(7):427. PubMed ID: 38869647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.
    Wong ML; Cooper BA; Paul SM; Abrams G; Topp K; Kober KM; Chesney MA; Mazor M; Schumacher MA; Conley YP; Levine JD; Miaskowski C
    Support Care Cancer; 2019 Oct; 27(10):3905-3912. PubMed ID: 30770977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced peripheral neurotoxicity: single-centre prospective study.
    Ben Kridis W; Toumi N; Khanfir A
    BMJ Support Palliat Care; 2024 Jan; 13(e3):e881-e884. PubMed ID: 37142330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Structural Equation Approach With the Theory of Unpleasant Symptoms.
    Kim M; Jung MS
    Cancer Nurs; 2021 Mar-Apr 01; 44(2):145-153. PubMed ID: 31833921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.